CPBNEUTRAL

P/E Ratio

10.5x

Updated 7h ago

Sector Performance

8th percentile

CPB

10.5x

Sector Median

24.7x

Sector Avg

36.0x

📊

Deep Analysis

The price-to-earnings (P/E) ratio of 10.5x means investors are paying $10.50 for every $1.00 of the company’s past-year earnings.

This is far below the sector median of 24.7x, placing CPB in the 8th percentile among sector peers — indicating a valuation well below typical industry levels. Over the last eight quarters the P/E ratio has shown an increasing trend, though the quarter-over-quarter change is -3.3% (from 10.9x to 10.5x), and no year-over-year comparison is available. The combination of a low P/E with a long-term upward trend suggests the stock may be undervalued relative to peers while gradually gaining investor attention, but the recent quarterly decline introduces a cautionary note about near-term momentum. This metric partially supports the NEUTRAL verdict: the low absolute P/E hints at potential upside, but the mixed trend and lack of clear improvement keep the outlook balanced rather than bullish or bearish.

Frequently Asked Questions

What does the P/E Ratio tell investors about CPB?

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.

How is the P/E Ratio calculated?

P/E Ratio is calculated as: Price / EPS.

Who are CPB's closest peers by P/E Ratio?

The closest peers by P/E Ratio include: VICI (9.1x), OMF (9.0x), JACK (8.5x), GIS (8.4x), FIS (8.4x).

The Formula

Price / EPS

Why It Matters

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.

Advertisement

Master CPB's Valuation

Get the complete institutional research report covering all fundamental and technical metrics.

View full CPB research report

Free account — no credit card

CPB

10.5x

Sector Median

24.7x

Sector Avg

36.0x

How CPB's P/E Ratio compares to sector peers.

Not financial advice. Research tool only. Data may be delayed.